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Booster Vaccinations
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Objective: To evaluate the immunogenicity of a combined DTPa-HB vaccine co-administered
with Haemophilus influenzae type b conjugate vaccine (PRP-T) in Brazilian infants. Material and
Methods: A prospective and open clinical study, in which 110 infants were immunized with a three-
dose primary vaccination regime at two, four and six months of age and with a single booster
vaccination. Blood samples were drawn immediately before the first dose, one month after the
third dose, at the time of the booster dose and one month after the booster to assess seropositivity
and antibody geometric mean titers (GMTs) of antibodies for diphtheria, tetanus, hepatitis B,
Haemophilus influenzae type b and for the three pertussis antigens: Pertussis Toxin (PT),
Filamentous Hemagglutinin (FHA) and Pertactin (PRN). Results: Among the original 110 infants,
93 completed the study. Seropositivity was 100% for all seven involved antibodies, after the
primary vaccination course. At the time of the booster dose, all antibodies (except diphtheria
33.7% and anti-PT 59%) were seropositive for more than 94% of subjects. After the booster,
seropositivity increased to 100% for all antibodies. The GMT of these antibodies followed a
similar pattern, with a strong increase after the primary course, followed by a second increase
after the booster dose. At this time, GMT was2- to 7-fold higher than after the primary course, for
all vaccine components. Conclusions: Concomitant administration of DTPa-HB and Hib vaccines
elicited strong seroprotection for all the antigenic components. No interference with antibody
response was evident. The vaccines provided high immunogenicity, following both the primary
vaccinations and the booster dose.
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The development of immunology and molecular
biology has, over recent years, promoted impressive
growth in the number of vaccines available [1]. Current
practice in pediatric vaccination is to stimulate the
utilization of vaccine combinations and concomitant
administration of vaccines, with the aims of diminishing
discomfort among vaccination patients and facilitating
adherence to the immunization scheme [2,3].
Inclusion of the vaccine against hepatitis B as a
component of a combined vaccine has the convenience
of improving adherence and consequently the
vaccination coverage. This is considered crucial for
reducing the dissemination of hepatitis B and the
associated morbidity and mortality [3,4]. The Pertussis
vaccine combined with Diphtheria and Tetanus toxoids,
the most widely disseminated and successful combined
vaccine, has served as the basis for most vaccine
combinations and presents the acellular pertussis
component as an alternative to traditional vaccines that
use whole cells, with similar efficacy and lower
reactogenicity [5]. Finally, combined or concomitant
administration of conjugated vaccine against
Haemophilus influenzae type b with other vaccines
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has taken on fundamental importance, as demonstrated
by the significant reduction in the incidence of the disease
seen in countries that have incorporated it into their
vaccination calendars [6,7].
Despite all the advantages of combined vaccines,
the physical, chemical or biological properties of each
vaccine component may interfere with the other
components. This may affect the stability, efficacy or
safety of the vaccine combination [3,8]. Moreover,
different populations may present varying responses
with regard to immunogenicity [9,10]. Thus, it is
important to determine whether or not the combined
or concomitant administration of several vaccines
diminishes the specific response for each vaccine
antigen, and to evaluate the resultant effect of including
one or more vaccine components in combination with
a vaccine that previously has been proven efficacious
in the immunogenicity of its components.
We examined the immunogenicity of a diphtheria-
tetanus-acellular pertussis vaccine (DTPa), combined
with the vaccine against hepatitis B (HB), and of a
vaccine against Haemophilus influenzae type b (PRP-
T), administered simultaneously to Brazilian children.
Material and Methods
This study was preceded by approval from the
National Commission for Research Ethics (Comissão
Nacional de Ética em Pesquisa - CONEP) and from
the Research Ethics Committees of Unifesp/Hospital
São Paulo and the Health Department of the
municipality of Embu, state of São Paulo. It was
developed at the Healthcare Unit of Jardim Santo
Eduardo, in the municipality of Embu, which is one of
the units in which the activities of the pediatrics team of
the Teaching-Attendance Integration Program of the
Federal University of São Paulo (Unifesp) are
concentrated. Written informed consent was obtained
from the parent or guardian of each subject prior to
entry into the study.
This was a prospective, open-label, single group
clinical study of the immunogenicity of a combined
diphtheria, tetanus, acellular pertussis and recombinant
Hepatitis B vaccine co-administered with Haemophilus
influenzae type b (Hib) vaccine as a primary
vaccination course in 110 healthy infants aged 2, 4 and
6 months, followed by a booster administered between
15 and 18 months of age. To investigate the
immunogenicity of the vaccines, blood samples were
drawn immediately before the first dose, one month
after the third dose, at the time of the booster dose and
one month after the booster (Figure 1).
Inclusion criteria were infants between 6 and 10
weeks of age at the time of the first vaccination, with
written informed consent obtained from the parents or
guardians of the subject. Exclusion criteria were history
of allergic disease likely to be stimulated by the
vaccination, history of progressive neurological disease,
immunosuppressive therapy, any suspected or
confirmed immunosuppressive or immunodeficient
condition, immunoglobulin therapy or administration of
any blood product since birth or during the study period.
The vaccines used in this study were developed and
manufactured by SmithKline Beecham Biologicals
(Rixensart, Belgium). A combined diphtheria, tetanus,
acellular pertussis, and hepatitis B vaccine (DTPa-
HBV) was supplied in a monodose vial. One dose (0.5
mL) of the combined DTPa-HBV contained: 25 µg
pertussis toxin (PT), 25 µg filamentous haemagglutinin
(FHA), 8µg pertactin (PRN), at least 30 IU
(international units) Diphtheria toxoid, at least 40 IU
Tetanus toxoid, 10 µg recombinant Hepatitis B surface
antigen (HbsAg), 0.7 mg aluminum (as a salt) and 2.5
mg phenoxyethanol. The Haemophilus influenzae
type b conjugate vaccine (Hib) was presented as a
freeze-dried pellet in a monodose vial to be
reconstituted before use with a sterile saline diluent (9
mg NaCl/mL), and one dose (5mL) contained 10 µg
Polyribosyl-Ribitol-Phosphate, between 20 and 40 µg
Tetanus toxoid and 12.6 mg lactose. The vaccines were
administered as separate, concomitant, deep
intramuscular injections in opposite limbs into the
anterolateral part of the thigh.
Blood samples were centrifuged and separated. All
serum samples were stored at –20ºC and shipped for
testing at SmithKline Beecham Biologicals laboratory
in Rixensart, Belgium. Antibodies against each vaccine
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antigen were determined by serological assays,
calibrated with international standards. Antibodies
against diphtheria, tetanus, pertussis components (PT,
FHA, PRN) and Hib (PRP) were determined by
enzyme-linked immunosorbent assay (ELISA). Anti-
diphtheria and anti-tetanus titers were expressed in IU/
mL and calibrated against the WHO reference serum
[11]. It is generally accepted for both antibodies that
titers greater than 0.01 IU/mL, measured by in vivo
neutralization tests, are protective. A good correlation
exists between neutralization tests and the ELISAs, but
this correlation may be reduced at titers lower than 0.1
IU/mL [12]. A titer of 0.1 IU/mL was therefore
conservatively used as the minimum titer indicative of
protection. Antibodies against PT, FHA and PRN
antigens were calibrated with the Food and Drug
Administration (FDA) reference serum, considered an
international standard [13], and the cut-off for all three
pertussis antibodies was set at 5 enzyme-linked
immunosorbent assay units (EL.U)/mL. The anti-PRP
antibody concentration of 0.15 µg/mL was set as the
cut-off. A serum concentration greater than 1 µg/mL
was also considered predictive of long-term protection
against Hib invasive disease. Antibodies against
Hepatitis B surface antigen were measured in milli-
International Units (mIU/mL) by radioimmunoassay
(AUSAB, Abott Laboratories), titered against a WHO
reference standard. The minimum antibody titer
necessary for protection against hepatitis B was
considered to be 10 mIU/mL, which is generally
accepted to be protective [14].
Seropositivity rate was defined as the proportion
of subjects with antibody titers greater than or equal to
the laboratory-defined assay cut-off value. The GMT,
with a 95% confidence interval (CI), was calculated
by taking the anti-log of the mean of the log-titer
transformations. Antibody titers below the cut-off level
were given an arbitrary value of half the cut-off value
for the purpose of GMT calculation. The data were
transcribed onto electronic media and processed on
an IBM-compatible microcomputer. The database
management and statistical analyses were performing
using Statistical Analysis Systems (SAS) 6.12 and
StatXact-3, both on Windows NT 4.0.
Results
Out of the 110 children who began the follow-up,
93 concluded the study 17 months later, thus
representing a loss of 15.5%. No child had any serious
adverse reaction, and all such occurrences have been
described in a specific study [15].
The seropositivity rates were determined for the
diphtheria and tetanus antigens at the four serum
collection times (Figure 2). For the diphtheria component,
more than 60% of the children already presented
antibody concentrations of more than 0.1 IU/mL before
starting the vaccination. One month after concluding the
basic scheme, all of the children had reached
concentrations greater than the cut-off value. Immediately
before the booster dose, the seropositivity rate was found
to have fallen considerably, down to around 30%. There
was a return to 100% seropositivity among the children
after the booster dose. The seropositivity rate against
the tetanus antigen before starting the vaccination was
also close to 60%. After the basic scheme, 100% of the
children reached protective levels. At the time of the
booster dose, this rate had fallen slightly, but it returned
to 100% after the booster.
The seropositivity rate was determined for the
antigens of the pertussis component (Figure 3). Before
starting the vaccination, the filamentous hemagglutinin
antigen (FHA) gave the highest seropositivity, with more
than 90% of the children already seropositive at that
time. After the primary immunization, the three antigens
(pertussis toxin, FHA and pertactin) attained a
seropositivity rate of 100%. Before the booster dose,
the seropositivity for the pertussis toxin (PT) had fallen
to a rate of less than 60%. The other two antigens
presented rates of close to 100% at this time. After the
booster dose, the seropositivity rate again reached
100% for the three antigens.
The seropositivity rate for the Hepatitis B surface
antigen (HbsAg) was determined (Figure 4). Before
starting the vaccination, less than 2% of the children
were seropositive. After the basic scheme, 100% of
the children attained protective levels. This percentage
had fallen slightly by the time of the booster dose, and
it returned to 100% after this dose.
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Figure 1.  Schematic representation of the study schedule.
Figure 2. Seropositivity rate for diphtheric and tetanic antigens, according to the blood sampling time point.
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Figure 3. Seropositivity rate for the three Pertussis component antigens (PT, FHA e PRN), according to the
blood sampling time point.
Figure 4. Seropositivity rate for Hepatitis B surface antigen (HbsAg), according to the blood sampling time point.
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Figure 5.  Proportion of subjects with titers greater than 0.15 µg/mL and 1 µg/mL for anti-PRP, according to the
blood sampling time point.
Table 1. Geometric mean titer for antibodies against the enrolled vaccine antigens, according to the blood sampling
time point
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Blood Sampling Time point
Antigen Pre vaccine Post dose 3 Pre booster Post booster
GMT GMT  GMT GMT
Diphtheria(IU/mL) 0.3 1.3 0.08 5.01
CI (95%) (0.22-0.40) (1.20-1.54) (0.07-0.08) (4.07-6.17)
Tetanus (IU/mL) 0.25 3.62 0.48 14.18
CI (95%) (0.18-0.34) (3.09-4.24) (0.39-0.58) (11.85-16.98)
PT (EL U/mL) 4.4 55.1 5.1 116.3
CI (95%) (3.8-5.2) (49.0-62.0) (4.4-5.8) (98.1-138.0)
FHA (EL U/mL) 18.5 290.8 38.3 851.5
CI (95%) (15.6-21.9) (254-333.0) (32.4-45.3) (753.9-961.7)
PRN (EL U/mL) 4.1 183.1 16.8 595.7
CI (95%) (3.5-4.8) (158.2-211.9) (14.3-19.9) (496.5-714.8)
HBs (mIU/mL) 5.24 1328.52 107.69 5093.17
CI (95%) (4.84-5.67) (1,037.57-1,701.04) (79.98-145.01) (3,725.52-6,962.90)
PRP (mg/mL) 0.15 18.59 2.15 129.1
CI (95%) (0.12-0.19) (13.71-25.22) (1.60-2.88) (96.84-172.11)
CI = Confidence intervals. GMT = Geometric mean antibody titer. IU = International units. EL U/mL = ELISA units per
milliliter.
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The seropositivity rate for the Polyribosyl-Ribitol-
Phosphate (PRP) antigen was expressed using two
different values (Figure 5). In addition to the cut-off
value of 0.15 µg/mL, which gives an estimation of the
minimum level for protection, the seropositivity rate with
a level of anti-PRP antibodies greater than or equal to
1 mg/mL was also calculated. This latter gives an
estimate for long-term protection.
When the GMTs for the diphtheria, tetanus, PT, FHA,
PRN, HBs and PRP antigens (Table 1) were compared,
all the vaccine components were found to present a
similar evolution, with a marked rise in antibody titers
after the basic scheme, followed by a decline over the
period immediately preceding the booster dose. After
this, there was a new increase in antibodies, which
exceeded the concentrations reached after the basic
scheme by a factor of two to seven (Table 2).
Discussion
Comparison of the results from this study with those
from other studies that utilized the same vaccines or
their components helps comprehend the
immunogenicity of the vaccines. Before the first
immunization, the anti-diphtheria and anti-tetanus
antibodies presented high levels (seropositivity rate of
around 60% for both antibodies). This was probably
the result of passage through the placenta and thus
reflects the mother’s state of vaccination. After the basic
scheme, there was a rise in the antibody titers. The
GMT for the anti-diphtheria and anti-tetanus antibodies
(respectively, 1.3 and 3.6 IU/mL) were similar to those
found in an American study for the same vaccine
(respectively, 1.81 and 3.44 IU/mL) [4]. The study by
Yeh et al. (2001), for the same vaccine combination
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Table 2. Relation between the post booster geometric mean antibody titer (GMT) and the post basic vaccination
GMT and between the post booster GMT and the pre booster GMT according to the antibody
Antibody GMT Post booster / GMT Post booster /
GMT Post basic vaccination GMT Pre booster
Diphtheria antitoxin 3.9 62.6
Tetanus antitoxin 3.9 30.2
Anti-PT 2.1 22.8
Anti-FHA 2.9 22.2
Anti-PRN 3.3 35.5
Anti-HBs 3.8 47.3
Anti-PRP 6.9 60.2
Table 3. Geometric mean antibody titers (in EL U/mL) to the three Pertussis antigens after basic vaccination,
compared with other studies
Studies GMT (EL U/mL)
anti-PT anti-FHA anti-PRN
This study 55.1 290.8 183.1
Greenberg et al., 2002 [4] 68.8 501 205
Yeh et al., 2001 [16] 72.8 234.3 154.9
Giammanco et al., (1998) [21] 56.1 153 240
GMT = Geometric mean antibody titer. EL U/mL = ELISA units per milliliter.
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and simultaneous application of inactivated polio vaccine
(IPV) and PRP-T vaccines, also reported similar
results, with GMT of 1.2 IU/mL for anti-diphtheria
antibodies and 2.3 IU/mL for anti-tetanus antibodies,
and all of the vaccinated patients attained a protective
seropositivity rate after completing the basic
immunization scheme, as we also found in our study
[16]. There was a decline in anti-diphtheria and anti-
tetanus antibody titers before the booster dose. The
values obtained (GMT of 0.08 IU/mL and seropositivity
rate of 33.7% for diphtheria, and GMT of 0.47 IU/mL
and seropositivity rate of 93.9% for tetanus) were similar
to those obtained in another study [16], which found a
GMT of 0.1 IU/mL and a seropositivity rate of 64.4%
for diphtheria, and a GMT of 0.5 IU/mL and a
seropositivity rate of 100% for tetanus; these authors
utilized the same serological test (ELISA). To determine
the negative anti-diphtheria antibody titers, by ELISA,
the authors  [16] utilized the Vero cell neutralization
test; when these two tests (ELISA and Vero cell
neutralization) were used, the seropositivity rate rose
from 64.4% to 90.3%. This suggests that the large fall
in anti-diphtheria antibodies observed immediately prior
to the booster dose was mainly due to the serological
method utilized, since the neutralization test has greater
sensitivity for detecting the immunological response for
diphtheria when the antibody titer is less than 0.1 IU/
mL and therefore ELISA underestimates the
seroprotection rate for this group [17]. The large
increase in concentrations of these two antibodies that
occurred after the booster dose, in relation to the
concentrations found immediately before this dose, was
also found in an American study [16]. However, in that
study, the GMT findings for both the anti-diphtheria
antibodies (5.01 IU/mL vs. 2.0 IU/mL) and the anti-
tetanus antibodies (14.18 IU/mL vs. 6.1 IU/mL) were
about twice the level that we found. However, in both
studies the seropositivity rates became 100% for both
antibodies, and the GMT values after the booster dose
exceeded the pre-booster values by a factor of at least
12.
We examined the GMTs of the three antigens that
made up the pertussis component (PT, FHA, PRN)
after the basic vaccination schedule scheme their and
compared them with the values found in other studies
(Table 3). The differences found in comparison with
these other studies, which utilized the same vaccine and
the same serological tests, may be due to variation in
the antibody response to the antigens in different
populations. The relevance of the differences found
diminishes when it is considered that the seropositivity
rate was 100% for the three vaccine antigens, both in
our study and in the three other studies with which it
was compared.
Differing from the other antigens for which minimum
levels of protection have been established, there is
currently no laboratory measurement for
immunogenicity that can be correlated with protective
efficacy for the antigens of the pertussis component
[5]. Consequently, the immunogenicity of the combined
vaccine after the basic scheme in our study was
compared with the immunogenicity found in a
multicenter study of acellular pertussis vaccines
(MAPT) promoted by the American National Institute
of Allergy and Infectious Diseases. The latter was
developed using the same diphtheria-tetanus-acellular
pertussis vaccine that serves as basis for our
combination vaccine. A field study in Italy demonstrated
84% efficacy for this DTPa vaccine [18]. Since the
GMT were similar to (55.1 U EL/mL vs. 54 U EL/mL
for the anti-PT antibody and 183.1 U EL/mL vs. 185
U EL/mL for the anti-PRN antibody) or greater than
(290.8 U EL/mL vs. 103 U EL/mL for the anti-FHA
antibody) those obtained in the multicenter study [19],
the comparison of the results demonstrates that the
combination of the DTPa (diphtheria-tetanus-acellular
pertussis) vaccine with the vaccine against hepatitis B
did not result in decreased immunogenicity of the
pertussis component of this combination, when
compared to the uncombined DTPa vaccine.
Consequently, this combination did not interfere in
vaccine efficacy.
At the time of the booster dose, the titers of the
three antibodies of the pertussis component presented
a large fall in relation to the titers found right after the
basic scheme. When compared with another study, for
the same vaccine, it was found that the titers were lower
for the three antibodies (anti-PT 5.1 vs. 8.4 U EL/mL;
Combined DTPa-HB Vaccine Co-Administered with PRP-T
www.bjid.com.br
BJID 2005; 9 (October) 371
anti-FHA 38.3 vs. 49 U EL/mL; and anti-PRN 16.8
vs. 25 U EL/mL) [16]. However, when the results from
the post-booster dose were compared with those from
the other study [16], the titers were higher for the three
antibodies (anti-PT 116.3 vs. 100 U EL/mL; anti-FHA
851.5 vs. 280 U EL/mL; and anti-PRN 595.7 vs. 303
U EL/mL) [16]. The children who  did not present any
seropositivity for one of the pertussis antigens before
the booster dose responded to the booster dose. The
large rise in GMTs for the three pertussis antigens in
relation to the levels prior to this dose, indicates effective
previous sensitization and immunological memory.
When hepatitis B applied as avaccine component
was compared with vaccine against hepatitis B applied
separately in the same vaccination scheme, the GMT
obtained after the basic scheme (1,328.52 mIU/mL)
was less than was obtained by Greenberg et al., in 1996
(1,812 mIU/mL), and greater than was obtained by
Yeh et al., in 2001 (805 mIU/mL), with a seropositivity
rate similar to what was found in the two studies (99%
and 100%) [16,20]. In comparison with other studies
that involved the same combined vaccine after the basic
scheme, the anti-HBs GMT was greater than what was
obtained by Giammanco et al. (949 mIU/mL), Yeh et
al. (919 mIU/mL) and Greenberg, in 2002 (1052 mIU/
mL) [4,16,21]. Although the need for a booster dose
is a subject for debate [22], it is certain that no booster
dose would be needed during a period of 9-12 months
after the third vaccine dose. The application of such a
dose would have the objective of assessing the
immunological memory triggered by the antigen stimulus.
The rise in the GMT for anti-HBs to more than 5000
mIU/mL and the approximately 50-fold increase in the
GMT for anti-HBs after the booster dose, in
comparison with the pre-booster period, demonstrates
that there is a memory response.
One difficulty in including the vaccine against
hepatitis B as a component of a combined vaccine is in
the adaptation to the vaccination scheme. This may be
adapted provided that it does not alter the immunological
response [3,4]. When the vaccine against hepatitis B is
applied in the most traditional scheme (at birth and at
the ages of one and six months), the GMT is greater
than in the scheme of applying at the ages of two, four
and six months, although the antibody titers are also high
and all the children are protected against clinical disease
and chronic infection. The difference in vaccine response
found between the two schemes can be explained by
the well-known phenomenon in which when the interval
between the second and third vaccine doses is increased,
higher levels of anti-HBs are attained [23].
Another question that must be addressed regarding
the vaccine against hepatitis B is the age at which the
vaccination should start. The World Health Organization
(WHO) recommends that, in countries with high levels
of perinatal transmission, a first dose of the vaccine
against hepatitis B should be given within the first 12
hours of life [24]. Studies have demonstrated that a
vaccine combination that includes the vaccine against
hepatitis B can be administered after one dose of the
vaccine against hepatitis B given at birth, without
increasing reactogenicity and with increased anti-HBs
antibodies [25,26]. On the basis of these data, a
vaccination scheme can be developed, consisting of
one dose of vaccine against hepatitis B, applied at birth,
followed by the combined doses at two, four and six
months, or alternatively without the need for the
component of the vaccine against hepatitis B at the age
of four months.
When the response to the vaccine against
Haemophilus influenzae type b (Hib) was evaluated, it
was found that after the basic scheme, the GMT for anti-
PRP antibodies (18.59 mcg/mL) was around two to three
times greater than the means observed in other studies
that also utilized anti-PRP vaccine conjugated with tetanus
toxoid that was applied concomitantly with DTPa-HB
vaccine, albeit manufactured by another laboratory
(Aventis-Pasteur): 6.26 mcg/mL [27], 7.1 mcg/mL [16]
and 9.8 mcg/mL [4]. Between nine and twelve months
after the conclusion of the basic scheme (pre-booster
period), the GMT was greater than was observed in
another study (2.15 mcg/mL vs. 1.2 mcg/mL) as was
the seropositivity rate for anti-PRP concentrations
greater than 1 mcg/mL (69.4% vs. 60%) [16]. In both
studies, after the booster dose, the seropositivity rate
for anti-PRP concentrations greater than 1 mcg/mL was
100%, although the GMT was around five times greater
in our study (129.1 mcg/mL vs. 27 mcg/mL) [16].
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In a comparison of the concentrations of anti-PRP
antibodies found after applying the basic vaccination
scheme concomitantly, with another study in which the
vaccine against Hib was administered in combination
with the DTPa vaccine and the vaccine against hepatitis
B (DTPa-HB/Hib), a large difference in anti-PRP
concentration was found (18.59 mcg/mL vs. 4.05 mcg/
mL) [28]. This difference was already expected, since
large numbers of reports have noted a marked reduction
in the response to PRP following primary immunization.
This has been observed with most of the vaccine
combinations in the acellular pertussis vaccine and the
vaccine against Hib (DTPa-Hib). The mechanisms
involved in this interaction, and also the clinical
repercussions coming from this reduction, are still
polemical points and motives for discussion within the
scientific community [5,29,30].
It is therefore concluded that the concomitant
administration of the combined DTPa-HB vaccine with
the anti-Haemophilus influenzae type b vaccine induces
a powerful antibody response to all the antigen
components. The antibody titers for all the vaccine
components presented a large rise after the basic scheme,
followed by a decline within the period immediately prior
to the booster dose. After this, a new increase in antibodies
was found, and this exceeded the titers attained after the
basic scheme by a factor of two to seven times, thereby
showing immunological memory. The seropositivity rate
after the basic scheme was 100% for all the antigens
(diphtheria, tetanus, PT, FHA, PRN, HBs and PRP).
Before the booster dose, all the antigens had seropositivity
rates of more than 94%, except for diphtheria, which
underwent a large fall and reached 33.7%, and pertussis
toxin with a rate of 59%. After the booster dose, the
seropositivity rate once again became 100% for all
antigens. These vaccines were immunogenic both after
the primary immunization and after the booster dose.
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